deaths (OS)

mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)

versus capecitabine
atezolizumab plus bevacizumab vs. capecitabine 1 certainty unassessable-6%